Abstract Objective To evaluate the clinical efficacy and safety of stereotactic radiotherapy(SRT) combined with bevacizumab for brain metastases in patients with lung adenocarcinoma. Methods The clinical data of 95 patients with brain metastases of lung adenocarcinoma were retrospectively analyzed, including 36 patients treated with SRT and bevacizumab (bevacizumab group) and 59 patients treated with SRT, corticosteroids, and mannitol (traditional drug group). The tumor response rate, peritumoral edema control rate, improvement in Karnofsky Performance Scale (KPS) score, and adverse reactions were analyzed. Results Compared with the traditional drug group, the bevacizumab group had significantly higher tumor response rate (P=0.033) and peritumoral edema control rate (P=0.000) at 1-4 weeks after treatment, as well as an obvious improvement in KPS score and reduced doses of corticosteroids and mannitol. In addition, the adverse reactions in the bevacizumab group were mild and controllable. Conclusions SRT combined with bevacizumab for brain metastases in patients with lung adenocarcinoma can achieve higher short-term tumor response rate and peritumoral edema control rate and improve patients’ quality of life.
Fund:Research Project of Shanghai Corps Hospital of Chinese People′s Armed Police Forces (2014KY11);Evaluation of the Apllication of Stereotactic Radiotherapy Equipment (2017YFC00113700)
Cite this article:
Pan Mianshun,Li Yong,Qiu Shujun et al. Efficacy and safety of stereotactic radiotherapy combined with bevacizumab for brain metastases of lung adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 880-883.
Pan Mianshun,Li Yong,Qiu Shujun et al. Efficacy and safety of stereotactic radiotherapy combined with bevacizumab for brain metastases of lung adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 880-883.
[1] Gavrilovic IT,Posner JB.Brain metastases:epidemiology and pathophysiology[J].J Neurooncol,2005,75(1):5-14.DOI:10.1007/s11060-004-8093-6. [2] Preusser M,Capper D,Ilhan-Mutlu A,et al. Brain metastases:pathobiology and emerging targeted therapies[J].Acta Neuropathol,2012,123(2):205-222.DOI:10.1007/s00401-011-0933-9. [3] Fábián K,Gyulai M,Furák J,et al. Significance of primary tumor location and histology for brain metastasis development and peritumoral brain edema in lung cancer[J].Oncology,2016,91(5):237-242.DOI:10.1159/000447517. [4] Goncalves PH,Peterson SL,Vigneau FD,et al. Risk of brain metastases in patients with nonmetastatic lung cancer:analysis of the metropolitan detroit surveillance,epidemiology,and end results (SEER) data[J].Cancer,2016,122(12):1921-1927.DOI:10.1002/cncr.30000. [5] Casanova N,Mazouni Z,Bieri S,et al. Whole brain radiotherapy with a conformational external beam radiation boost for lung cancer patients with 1-3 brain metastasis:a multi institutional study[J].Radiat Oncol,2010,5:13.DOI:10.1186/1748-717X-5-13. [6] Pan HC,Sun MH,Chen CC,et al. Neuroimaging and quality-of-life outcomes in patients with brain metastasis and peritumoral edema who undergo Gamma Knife surgery[J].J Neurosurg,2008,109 Suppl:90-98.DOI:10.3171/JNS/2008/109/12/S15. [7] Wang Y,Wang E,Pan L,et al. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema[J].J Neurooncol,2014,119(2):369-376.DOI:10.1007/s11060-014-1488-0. [8] Patchell RA,Tibbs PA,Regine WF,et al. Postoperative radiotherapy in the treatment of single metastases to the brain:a randomized trial[J].JAMA,1998,280(17):1485-1489. [9] Shaw MG,Ball DL.Treatment of brain metastases in lung cancer:strategies to avoid/reduce late complications of whole brain radiation therapy[J].Curr Treat Options Oncol,2013,14(4),553-567.DOI:10.1007/s11864-013-0258-0. [10] 李勇,潘绵顺,邱书珺,等.非小细胞肺癌脑转移瘤的立体定向放射治疗[J].中华神经外科杂志,2014,30(7):711-714.DOI:10.3760/cma.j.issn.1001-2346.2014.07.019. Li Y,Pan MS,Qiu SQ,et al. Stereotactic radiotherapy for brain metastases of non-small cell lung cancer[J].Chin J Neurosurg,2014,30(7):711-714.DOI:10.3760/cma.j.issn.1001-2346.2014.07.019. [11] Kaal EC,Vecht CJ.The management of brain edema in brain tumors[J].Curr Opin Oncol,2004,16(4):593-600. [12] Senger DR,Galli SJ,Dvorak AM,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid[J].Science,1983,219(8):983-985. [13] Dvorak HF,Sioussat TM,Brown LF,et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors:concentration in tumor blood vessels[J].J Exp Med,1991,174(10):1275-1278. [14] Jiang S,Xia R,Jiang Y,et al. Vascular endothelial growth factors enhance the permeability of the mouse blood-brain barrier[J/OL].PLoS One,2014,9:e86407.DOI:10.1371/journal.pone.0086407. [15] Schmid S,Aboul-Enein F,Pfisterer W,et al. Vascular endothelial growth factor:the major factor for tumor neovascularization and edema formation in meningioma patients[J].Neurosurgery,2010,67(15):1703-1708.DOI:10.1227/NEU.0b013e3181fb801b. [16] Stewart MW.Anti-VEGF Therapy for Diabetic Macular Edema[J].Curr Diab Rep,2014,14(4):510.DOI:10.1007/s11892-014-0510-4. [17] 潘绵顺,李勇,邱书珺,等.贝伐单抗治疗放射性脑坏死初步疗效分析[J].中华放射肿瘤学杂志,2015,24(4):434-437.DOI:10.3760/cma.j.issn.1004-4221.2015.04.020. Pan MS,Li Y,Qiu SQ,et al. Analysis of bevacizumab in the treatment of radiation-induced brain necrosis preliminary efficacy[J].Chin J Radiat Oncol,2015,24(4):434-437.DOI:10.3760/cma.j.issn.1004-4221.2015.04.020. [18] Kozin SV,Boucher Y,Hicklin DJ,et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-inducedlong-term control of human tumor xenografts[J].Cancer Res,2001,61(1):39-44.
2017, Vol. 26 
